Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LB1908 · 1 trial · 4 indications
Multiple doses will be tested to establish a recommended dose.
Treatment of additional patients at the recommended dose as identified in the initial dose escalation part of the study.
| Arm | Type | Description |
|---|---|---|
| Experimental LB1908 | EXPERIMENTAL | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells |
| Name | Type | Description |
|---|---|---|
| LB1908 | BIOLOGICAL | Claudin 18.2-Targeted autologous Chimeric Antigen Receptor T-cells |
Inclusion Criteria: For inclusion in the study, all of the following inclusion criteria must be fulfilled. 1. Be willing and able to provide written informed consent. 2. Be a female or male ≥ 18 and ≤ 75 years old at the time of signing of the prescreening ICF. 3. For Part A and Part B Cohort MR1 ...
Top 20 of 45 competitors
LB1908 is an investigational monoclonal antibody being developed for the treatment of gastric cancer. It is currently in Phase 1 clinical development for this indication. The drug is being studied in patients with unresectable, locally advanced, or metastatic gastric cancer.
LB1908 targets CLDN18.2, a protein that is expressed in certain cancer cells. By binding to this target, the drug is designed to interfere with cancer cell growth. CLDN18.2 is a specific molecular target being investigated in oncology for its role in gastric and other gastrointestinal cancers.
LB1908 is being developed by Legend Biotech Corporation, a biopharmaceutical company. Legend Biotech is publicly traded on the Nasdaq stock exchange under the ticker symbol LEGN. The company is conducting clinical trials to evaluate the safety and efficacy of LB1908.
LB1908 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial is active but not recruiting participants, and is designed to assess the drug's safety, tolerability, and preliminary efficacy.
LB1908 is being studied in a Phase 1 clinical trial with the identifier NCT05539430. This trial is enrolling patients with gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma. The study is active but not recruiting, with a planned enrollment of 56 participants in the United States.
LB1908 is a monoclonal antibody, not a CAR-T therapy. However, the clinical trial NCT05539430 is investigating a Claudin 18.2-targeted chimeric antigen receptor T-cell therapy in similar patient populations. LB1908 itself is a separate investigational drug being developed by Legend Biotech.